Trading Report: The Dimension Therapeutics Inc. (DMTX) Cut to Sell at Zacks Investment Research

The Dimension Therapeutics Inc. (DMTX) Cut to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Dimension Therapeutics Inc. (NASDAQ:DMTX) from a hold rating to a sell rating in a research report released on Monday.

According to Zacks, “Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company’s pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts. “

A number of other research analysts also recently weighed in on the stock. Jefferies Group set a $12.00 target price on shares of Dimension Therapeutics and gave the company a buy rating in a research report on Monday, September 12th. Chardan Capital set a $10.00 target price on shares of Dimension Therapeutics and gave the company a hold rating in a research report on Sunday, August 21st. Canaccord Genuity set a $20.00 target price on shares of Dimension Therapeutics and gave the company a buy rating in a research report on Thursday, August 11th. Finally, Cantor Fitzgerald reaffirmed a buy rating on shares of Dimension Therapeutics in a research report on Wednesday, June 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $17.19.

Dimension Therapeutics (NASDAQ:DMTX) opened at 6.49 on Monday. Dimension Therapeutics has a 12 month low of $5.39 and a 12 month high of $15.55. The firm’s market cap is $162.44 million. The stock’s 50 day moving average is $7.79 and its 200-day moving average is $7.43.

Dimension Therapeutics (NASDAQ:DMTX) last released its earnings results on Thursday, August 11th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.06. Dimension Therapeutics had a negative net margin of 459.47% and a negative return on equity of 66.58%. On average, analysts anticipate that Dimension Therapeutics will post ($1.91) earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of DMTX. FIL Ltd bought a new stake in Dimension Therapeutics during the second quarter worth about $10,133,000. Vanguard Group Inc. boosted its stake in Dimension Therapeutics by 447.4% in the second quarter. Vanguard Group Inc. now owns 426,165 shares of the company’s stock worth $2,557,000 after buying an additional 348,311 shares in the last quarter. BlackRock Fund Advisors boosted its stake in Dimension Therapeutics by 119.2% in the second quarter. BlackRock Fund Advisors now owns 317,232 shares of the company’s stock worth $1,903,000 after buying an additional 172,495 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Dimension Therapeutics by 50.5% in the first quarter. JPMorgan Chase & Co. now owns 239,000 shares of the company’s stock worth $1,871,000 after buying an additional 80,200 shares in the last quarter. Finally, Weiss Multi Strategy Advisers LLC boosted its stake in Dimension Therapeutics by 17.8% in the second quarter. Weiss Multi Strategy Advisers LLC now owns 235,549 shares of the company’s stock worth $1,413,000 after buying an additional 35,549 shares in the last quarter. Institutional investors own 85.80% of the company’s stock.

About Dimension Therapeutics

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Related posts

Leave a Comment